Guenther Koehne, MD
Medical Oncology · Miami, FLNPI 1679791818
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,134 of the $37,674 with a category attached, or 69.4%. Astellas Pharma US Inc accounts for 74.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $30,641 and has fallen 90.1% since, to $3,022 in 2025.
Across 45 payments — averaging $837.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$28K
- Gamida Cell Inc.$3K
- Jazz Pharmaceuticals Inc.$3K
- Janssen Scientific Affairs, LLC$2K
- Astellas Pharma Global Development$648
- Bristol Myers Squibb$331
- plus $1K from 10 others
Across 159 payments — averaging $6106.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$695K
- Bristol Myers Squibb$85K
- Jazz Pharmaceuticals Inc.$55K
- Karyopharm Therapeutics Inc.$41K
- Redhill Biopharma Inc.$39K
- ADC Therapeutics America, Inc.$37K
- plus $20K from 2 others
What the payments were for
- Consulting fees$7,12019%
- Speaking & faculty fees$26,13469%
- Travel & lodging$2,2376%
- Food & beverage$2,0846%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 16 | $27,877 |
| Gamida Cell Inc. | 2 | $2,825 |
| Jazz Pharmaceuticals Inc. | 5 | $2,818 |
| Janssen Scientific Affairs, LLC | 2 | $2,080 |
| Astellas Pharma Global Development | 1 | $648 |
| Bristol Myers Squibb | 3 | $331 |
| Eurofins Viracor, LLC | 1 | $283 |
| AstraZeneca | 2 | $234 |
| Sanofi | 2 | $142 |
| Johnson & Johnson | 3 | $106 |
| Gilead | 2 | $94 |
| Sumitomo Pharma America, Inc. | 1 | $74 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| GSK | 2 | $44 |
| Seagen Inc. | 1 | $36 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,674 in reported general payments places this provider in the 80th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Sarbajit MukherjeeMiami$232K
- Bruna Pellini FerreiraMiami$158K
- Coral OlazagastiMiami$134K
- Jonathan TrentMiami$102K
- Gilberto LopesMiami$99K
- Craig MoskowitzMiami$94K
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.